Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This is a global randomized, placebo-controlled, double-blinded Phase 2 study designed to
compare treatment of ARQ 197 versus placebo in patients with unresectable HCC who had
radiographic disease progression after systemic first line therapy or were unable to tolerate
the therapy.
Phase:
Phase 2
Details
Lead Sponsor:
ArQule ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)